Lingkang Pharmaceutical: Achieved a turnaround from loss to profit in the first half of 2026, with a net profit of 21.1127 million yuan.

Lincan Pharmaceutical announced that in the first half of 2026, operating income reached 257 million yuan, an increase of 50.03% year-on-year. The net profit attributable to shareholders of the listed company was 21.1127 million yuan, compared to a net loss of 35.7337 million yuan in the same period last year, achieving a turnaround from loss to profit. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 18.4208 million yuan. The company will not distribute profits or increase capital reserves for the first half of the year.